From the Parc Científic de Barcelona and
Departament de Bioquímica i Biologia Molecular, Facultat de
Biologia, Universitat de Barcelona, Barcelona 08028, Spain, the
¶ Institut National de la Santé et de la Recherche
Médicale Unité-449 and Centre de Recherche en Nutrition
Humaine de Lyon, Faculté de Médecine R.T.H. Laennec,
F-69372 Lyon, France, the
Servei Hormonal, Hospital
Clìnic i Provincial, Barcelona 08036, Spain, the
** Departament de Fisiologia (Biología del
Macrófago, Immunologia), Facultat de Biologia, Universitat de
Barcelona, Barcelona 08028, Spain, the
Department of Clinical Physiology,
Karolinska Hospital, SE-17177 Stockholm, Sweden, and the
§§ MRC Dunn Human Nutrition Unit, Wellcome
Trust/MRC Building, Hills Road,
Cambridge CB2 2XY, United Kingdom
Received for publication, December 16, 2002, and in revised form, February 6, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In many cells and specially in muscle,
mitochondria form elongated filaments or a branched reticulum. We show
that Mfn2 (mitofusin 2), a mitochondrial membrane protein that
participates in mitochondrial fusion in mammalian cells, is induced
during myogenesis and contributes to the maintenance and operation of
the mitochondrial network. Repression of Mfn2 caused morphological and
functional fragmentation of the mitochondrial network into independent
clusters. Concomitantly, repression of Mfn2 reduced glucose oxidation,
mitochondrial membrane potential, cell respiration, and mitochondrial
proton leak. We also show that the Mfn2-dependent mechanism
of mitochondrial control is disturbed in obesity by reduced Mfn2
expression. In all, our data indicate that Mfn2 expression is crucial
in mitochondrial metabolism through the maintenance of the
mitochondrial network architecture, and reduced Mfn2 expression may
explain some of the metabolic alterations associated with obesity.
In many cell types, especially muscle fibers,
mitochondria form tubular structures or networks (1, 2). In fibroblasts and cardiomyocytes, mitochondrial filaments conduct mitochondrial membrane potential (3, 4). The electrical activity of the mitochondrial
network in large cells such as muscle fibers may permit the movement of
energy from the cell periphery to the cell core.
There is evidence in Saccharomyces, Aspergillus,
and mammalian cells that mitochondrial filaments are highly dynamic
structures (5-7). In yeast this dynamic is regulated by changes in the
rates of mitochondrial fission and fusion. Based on the isolation and analysis of yeast mutants that are defective in mitochondrial division
and fusion, several laboratories have isolated proteins that mediate
mitochondrial fission and fusion (8, 9). Mitochondrial fusion in yeast
and Drosophila depends on the integrity of the fzo gene that encodes a mitochondrial transmembrane
GTPase (10, 11). Thus, loss of function of fzo causes
fragmentation of mitochondrial tubules in yeast (11) and alteration of
spermatogenesis and male sterility in Drosophila (10). Yeast
Dnm1p and Mgm1p proteins (12-14) are structurally related to the
dynamin GTPase and also contribute to mitochondrial fission (15, 16).
Dnm1p operates in conjunction with Mdv1/Fis2/Gag3 and Mdv2/Fis1 to
regulate mitochondrial fission (16-18). Because mammals have genes
that are homologous to fzo, Dnm, and Mgm1p (19-22), such
fusion and fission events may also be critical for the architecture of
mitochondrial networks in mammalian cells.
Tissues with high and variable rates of aerobic metabolism such as
skeletal muscle or heart show a more prominent development of the
mitochondrial network (1, 2), although this remains unexplained. In
addition, the extent of the mitochondrial network is regulated by
hypoxic conditions (23). These data suggest that the mitochondrial
network per se or proteins that participate in the
generation of the mitochondrial network may be involved in the control
of mitochondrial energy metabolism.
In this study, we screened differentially expressed genes in skeletal
muscle from obese Zucker rats, and we isolated the fzo homologue mitofusin 2 (Mfn2). We demonstrate that Mfn2 expression is
crucial to the maintenance of the morphology and operation of the
mitochondrial network and in mitochondrial metabolism. We also show
that this regulatory mechanism is disturbed in obesity.
Subtractive Hybridization--
Messenger RNA was extracted from
gastrocnemius muscle of control (fa/+) and obese (fa/fa)
rats with oligo(dT)20-cellulose columns, as described (24).
Complementary DNA was prepared from 2 µg of mRNA using
Superscript II (Invitrogen). A PCR-Select cDNA Subtraction kit
(Clontech) was used to select for genes that are down-regulated in the obese. The cDNA fragments obtained were arrayed on 96-well plates and screened using labeled cDNA from lean
or control rats.
Northern Blot--
Northern blot assays from 20 µg of total
RNA were performed as described (25) using as probes the
32P-labeled C31 cDNA fragment (321 bp) obtained from
the subtractive hybridization or the 32P-labeled stem-cell
factor cDNA fragment obtained by PCR. The C31 cDNA fragment is
identical to the nucleotide sequence 2098-2419 of the rat U41803
(GenBankTM).
Quantitative PCR--
Retrotranscription and
competitive-quantitative PCR was performed from 0.1 µg of total RNA
from vastus lateralis muscle from lean and obese subjects,
as described (26). Briefly, for each sample Mfn2 mRNA and an
internal competitor at different known concentrations were co-amplified
with the same pair of primers: 5'-atgcatccccacttaagcac-3' and
5'-ccagagggcagaactttgtc-3'. Mfn2 concentration was extrapolated from
the point at which both products are amplified to the same extent.
Subjects and Protocols--
Thirteen healthy lean volunteers
(51 ± 2 years; body mass index, 23 ± 1 kg/m2; blood glucose, 4.9 + 0.1 mmol/liter; plasma insulin,
34 ± 2 pmol/liter) and nine obese volunteers (46 ± 2 years;
body mass index, 34 ± 1 kg/m2; blood glucose, 4.9 + 0.1 mmol/liter; plasma insulin, 62 ± 6 pmol/liter) participated
in the study. Percutaneous biopsies of the vastus lateralis
muscle were obtained before a 3-h euglycemic hyperinsulinemic clamp
(insulin infusion rate of 12 pmol/kg/min), as described elsewhere (27).
Insulin-stimulated glucose utilization was determined as reported
(26).
Western Blot--
A rabbit antibody against the Mfn2 specific
peptide LGPKNSRRALMGYNDQVQRP was purchased from Research Genetics.
Anti-Porin antiserum was used as a mitochondrial marker. Proteins from
total homogenates or fractions enriched in mitochondria were resolved in 10% SDS-PAGE and transferred to Immobilon sheets. Incubation with
antibodies and ECL detection were performed as described (25).
Immunofluorescence Techniques and Mitochondrial
Staining--
Cells grown on coverslips were fixed for 20 min with 3%
paraformaldehyde in PBS,1
then washed three times in PBS, and incubated for 10 min in PBS containing 50 mM NH4Cl, 10 min in PBS
containing 20 mM glycine, and 30 min in PBS containing 10%
normal goat serum. Subsequently coverslips were incubated with primary
antibodies at 0.5-1.0 µg/ml (anti-COXI subunit, Molecular Probes,
Leiden, The Netherlands; anti-Myc 9E10, ATCC, Manassas, VA) diluted in
PBS containing 10% goat serum for 1 h at room temperature. After
washing in PBS, the coverslips were incubated with
fluorochrom-conjugated (Oregon Green or Texas Red) goat secondary
antibodies for 45 min. The cells were washed three times in PBS prior
to mounting in immunofluore medium (ICN Biomedicals Inc., Aurora, OH).
MitoTracker Red CXRos and JC-1 (Molecular Probes, The Netherlands) were
used to label mitochondria using the manufacturer's protocol. Briefly,
the cells were incubated with 0.5 µg/ml mitochondrial dye diluted in
DMEM incomplete medium at 37 °C for 30 min. Thereafter the cells
were washed in PBS warmed to 37 °C and fixed with 3%
paraformaldehyde in PBS or were processed in vivo. To assess
mitochondrial connectivity, the laser microirradiation technique was
applied to cause mitochondrial membrane perforation in living cells
previously stained with JC-1. A continuous argon laser (at Measurement of Mitochondrial Membrane Potential--
JC-1 is a
cationic fluorescent dye (green color as monomer; 539 nm) that
accumulates in mitochondria in a potential-dependent manner. Its accumulation in mitochondria leads to high concentrations of the dye and the subsequent formation of red fluorescent aggregates (597 nm). The concentration of JC-1 green monomers in the mitochondria increases proportionally to the membrane potential, and they form J-aggregates when green monomers concentration reach a certain level.
This critical concentration is reached when membrane potential exceeds
Measurement of Mitochondrial Volume and Surface Area in Skeletal
Muscle--
The volume and surface area of skeletal muscle
mitochondria were measured by the "vertical sections" method (30).
Soleus muscles from four obese Zucker rats and four control lean rats were fixed and sectioned in random orientations, always perpendicular to their longitudinal axis, and 80 photographs/group at 5,000× were
taken at random. The photographs were taken excluding the subsarcolemmal mitochondria population and always including Z-disc in
the field. For each image, the mitochondrial surface area and volume
were calculated from the number of randomly distributed points and
cycloid arcs in a grid. The number of points inside the mitochondria is
taken as the volume, and the number of cycloid arcs crossing the
mitochondrial outer membrane is taken as the area. The volume/area
ratio is an intrinsic parameter of mitochondria and does not depend on
number of mitochondria studied.
Transient and Stable Transfection Studies--
10T/2 fibroblasts
were grown in DMEM containing 10% FBS. A plasmid enclosing two
independent expression cassettes expressing Mfn2 and GFP was prepared
for transient transfection. Each expression cassette was driven by a
cytomegalovirus promoter and contained an SV40 polyadenylation signal.
Transfected cells were identified by GFP fluorescence. Cells
transfected with the empty vector were used as control. For electron
microscopy, the transfected cells were sorted using flow cytometry;
thereafter, GFP-expressing cells were pelleted and processed for Spurr
embedding and ultramicrotomy.
For stable transfection, IMAGE clone 3746-e24 was digested with
KpnI and XhoI, and the antisense fragment
corresponding to sequence 1-370 from mouse Mfn2 (GenBankTM
accession number AY028170) was purified and cloned into pcDNA3 vector (Invitrogen) between the XhoI and KpnI
sites. Geneticin selection at 500 µg/ml allowed isolation of
individual clones. All of the transfections were performed with 20 µg
of plasmid by the calcium phosphate method (31).
Production of Adenovirus--
Recombinant adenovirus expressing
GFP, lacZ, or antisense Mfn2 cDNA fragment were generated by
homologous recombination as previously described (32). The mouse Mfn2
sequence between nucleotides 1 and 370 was cloned in antisense
orientation in the shuttle plasmid pdelE1sp1A and co-transfected with
pJM17 into 293 cells to achieve homologous recombination. Individual
plaques were isolated and checked for mRNA expression after
infection of 293 cells. Recombinant adenovirus were further amplified
in 293 cells, purified by cesium chloride gradient centrifugation,
dialyzed against 1 mM MgCl2, 10 mM
Tris, pH 7.4, 10% glycerol and stored at Glucose Oxidation Measurements--
Glucose oxidation was
measured in cells expressing or not a Mfn2 antisense sequence. The
cells were incubated in Hanks' balanced salt medium (2% FBS, 5 mmol/liter glucose) containing 0.33 µM [14C](U)-D-glucose (323 Ci/mol) (Amersham
Biosciences), and 14CO2 was trapped and
measured as described (33).
Measurement of Cell Respiration Rates--
The respiration rates
were measured using two 2-ml Clark oxygen electrodes (Rank Brothers,
Bottisham, Cambridge, UK) at 37 °C and connected to a Kipp & Zonendual channel chart recorder, assuming 479 nmol O/ml at air
saturation. The cell respiration rates were expressed as a function of
cell number. The cells were diluted with Krebs-Ringer buffer
supplemented with 5 mM glucose and bovine serum albumin 2%
to 4.106 cells/ml in a 2-ml Clark electrode at 37 °C.
Inhibitors were used at times and concentrations that caused maximal
inhibition (data not shown), and the measurements were performed at
70% air saturation after at least 5 min. Respiration insensitive to
myxothiazol (200 µM) was defined as
nonmitochondrial, and respiration sensitive to myxothiazol was
defined as mitochondrial. Similarly, respiration sensitive to
oligomycin (80 µg/ml) was defined as coupled respiration, and
respiration insensitive to oligomycin but sensitive to myxothiazol was
defined as respiration driving proton leak or uncoupled respiration.
Mfn2 Is Highly Expressed in Muscle and Is Induced in
Myogenesis--
In a screening designed to identify genes
differentially expressed in obese Zucker rats using PCR-select cDNA
subtraction, we isolated a 321-bp clone (C31) that hybridized with a
4.7-kb mRNA species in skeletal muscle. C31 cDNA sequence was
identical to the sequence in GenBankTM between nucleotides
2098 and 2419 of rat U41803 and 79% identical to the human cDNA
sequence D86987 submitted by Nagase et al. (52) to
the GenBankTM and recently identified as mitofusin Mfn2
(22). Multi-alignment of human Mfn2 with other gene products showed
that it is 95% identical to the rat Mfn2 protein (U41308), 94%
identical to the mouse Mfn2 counterpart (GenBankTM
accession number AY028170), and 47% identical to Drosophila melanogaster Mfn2 (GenBankTM accession number
AF355475). Lower identity was found with the fzo gene
product from D. melanogaster (31% identity) (10) and that
from Saccharomyces cerevisiae (8% identity) (11). The tissue distribution of human Mfn2 mRNA was examined by Northern blot analysis at high stringency (Fig.
1A). The mRNA species of 4.7 kb hybridized with the 321-bp clone. Transcripts were predominant in skeletal muscle and heart, but expression was low in brain, kidney,
and liver (Fig. 1A). A similar distribution profile was detected in rat tissues (data not shown).
Based on the abundant expression of Mfn2 mRNA in skeletal muscle,
we examined whether the expression was regulated during myogenesis.
L6E9 myoblasts barely expressed Mfn2, but a marked induction of Mfn2
mRNA levels was detected with differentiation into myotubes (Fig.
1B).
A polyclonal antibody was raised against a Mfn2 sequence, which
detected a 110-kDa band in extracts from heart, skeletal muscle, brown
adipose tissue, and kidney in rats (Fig.
2A); the band was specifically
washed by an excess of the immunogenic peptide (Fig. 2A).
Endogenous Mfn2 was enriched in mitochondrial fractions in heart, brown
adipose tissue, and kidney (Fig. 2B), which is in keeping
with observations that overexpressed Mfn2 is found in mitochondria (22,
34). Under these conditions, we found that myogenesis caused the
induction of Mfn2 protein in L6E9 cells (Fig. 2C).
Mfn2 Induction Parallels the Development of the Mitochondrial
Network and Its Operation as an Intralumenally Connected
System--
Induction of Mfn2 gene expression in L6E9 myotubes was
parallel to the development of a very extensive mitochondrial network (Fig. 3, A and B).
Evidence for the operation of the mitochondrial network as an
intralumenally connected system in muscle cells was obtained by laser
microirradiation (3). In myoblast cells, a short portion of a
mitochondrial filament became de-energized when one of the
cluster-composing mitochondria was damaged by laser (Fig. 3,
C and D). As a consequence of the loss of
mitochondrial membrane potential, mitochondria became unstained by
JC-1. In contrast, illumination of a single mitochondrial filament in
L6E9 myotubes caused a generalized loss of mitochondrial membrane
potential throughout the mitochondrial network, and affecting areas
situated far from the irradiation spot (see Fig. 6, A and
B). These data indicate the existence of a very extensive
intralumenal connectivity in the mitochondria that form the
mitochondrial network in myotubes.
Mfn2 Controls the Generation and Operation of the Mitochondrial
Network--
To determine the precise role of Mfn2 on the
mitochondrial network, we performed studies in which Mfn2 expression
was up- and down-regulated. Overexpression of Mfn2 after transient
transfection collapsed the network in L6E9 myoblasts and mitochondria
clustered around the nucleus (Fig. 4,
A and B). Mitochondria in 10T1/2 fibroblasts are
also usually organized in filaments but rarely seen as isolated organelles (Fig. 4C). Overexpression of Mfn2 after transient
transfection also caused mitochondrial clustering around the nucleus
(Fig. 4D). This is in keeping with recent observations (22,
34). Transmission electron microscopy revealed that this clustering was
not due to the generation of giant mitochondria. Instead, it
corresponds to aggregates of mitochondria with normal ultrastructural morphology (Fig. 4, E and F). Both endogenous and
overexpressed Mfn2 protein was localized in mitochondria by biochemical
and immunofluorescence assays (data not shown). These data indicate that Mfn2 requires additional proteins to complete the full
mitochondrial fusion process.
To determine the impact of the repression of Mfn2 gene expression, we
knocked down Mfn2 expression in muscle cells. To this end, we generated
an adenoviral vector encoding a mouse Mfn2 antisense sequence (AS), and
this was used to infect L6E9 myotubes. AS adenoviral infection reduced
Mfn2 protein levels in mitochondrial extracts (by about 50%) in the
absence of alterations in the abundance of Porin (Fig.
5A). This effect was specific,
and infection with an irrelevant adenovirus, encoding
Mfn2 Controls Mitochondrial Metabolism--
Next, we examined
whether reduction in Mfn2 expression caused alterations in
mitochondrial metabolism. Repression of Mfn2 expression mediated by AS
adenoviral expression in L6E9 myotubes reduced glucose oxidation by
30% (Fig. 7A). This effect
was specific, and infection with an adenoviral vector encoding
We also stably transfected 10T1/2 cells with a mouse Mfn2 antisense
sequence. Mfn2 mRNA and protein levels were lower in antisense clones than in untransfected or mock transfected cells (Mfn2 protein levels ranged from 32 to 67% of control values in AS clones) (Fig. 8, A and B).
Repression of Mfn2 in 10T1/2 cells also reduced glucose oxidation by
30% (Fig. 8C). In addition, AS cells showed a 30% reduction in oxygen consumption (Fig. 8D). In these
conditions, coupled oxygen consumption was unaltered, whereas
respiration linked to the mitochondrial proton leak was significantly
reduced in AS cells (Fig. 8D). These data indicate that
reduction of Mfn2 expression causes alterations in mitochondrial
metabolism characterized by reduced cellular oxygen consumption and
depressed glucose oxidation.
Mfn2 Expression Is Repressed in Obesity--
Skeletal muscle in
human obesity is characterized by metabolic alterations, including
insulin resistance, accumulation of intracellular triglycerides,
reduced oxidation processes, and impaired glucose-induced thermogenesis
(36, 37). In some animal models of obesity such as in obese Zucker rats
or ob/ob mice, skeletal muscle shows a metabolic profile characterized
by reduced glucose uptake and glucose oxidation, altered partitioning
of fatty acids that are incorporated into triglycerides, or oxidized, insulin resistance and reduced oxygen consumption (38-43). In
particular, the mechanisms by which obesity leads to a deficient muscle
substrate oxidation remain unexplained and are concomitant with
unaltered mitochondrial activities of pivotal enzymes such as pyruvate
dehydrogenase, citrate synthase, succinate dehydrogenase, or
Based on the role of Mfn2 on mitochondrial metabolism, we determined
its expression in obesity. Expression of Mfn2 mRNA in Zucker obese
rats was 34% lower than in lean (Fig.
9A). We therefore measured the
gene expression of Mfn2 in skeletal muscle from obese human subjects.
Obese subjects were normoglycemic and hyperinsulinemic and showed 50%
lower insulin-stimulated glucose disposal as assessed by
euglycemic-hyperinsulinemic clamp (4.9 + 0.8 and 10.1 + 1.1 mg/kg/min
for obese and lean subjects, respectively) (27). Total RNA was purified
from vastus lateralis muscles from subjects, and reverse
transcriptase-competitive-quantitative PCR analysis was performed to
measure Mfn2 mRNA (Fig. 9B). Expression was 36% lower
in the obese subjects (Fig. 9B). A negative linear
relationship between Mfn2 mRNA levels and body mass index was
detected when all of the data were pooled (data not shown).
Next, we determined Mfn2 protein expression in mitochondrial fractions
from skeletal muscle. Expression of Mfn2 in Zucker obese rats was 39%
lower than in lean (Fig.
10A). In addition, Mfn2
expression in skeletal muscle from obese humans was 43% lower than
controls (Fig. 10B).
We next examined whether the mitochondrial network was modified in
skeletal muscle during obesity. To this end, muscles from obese Zucker
rats were obtained and processed for electron microscopy, and the
extent of the mitochondrial network was assessed as the ratio between
mitochondrial volume/unit of mitochondrial surface (30). No differences
were found in the total mitochondrial volume between control and obese
groups, indicating that the total mitochondrial mass was unaltered
(data not shown). In contrast, the density of mitochondria was higher
in the obese group (8.2 + 0.5 and 11.2 + 0.6 organelles/10
µm2 in control and obese groups, respectively;
p < 0.001) (Fig. 11, A and B). This suggests a smaller mitochondrial
size and a fragmented mitochondrial network in skeletal muscle during
obesity. In keeping with this view, total mitochondrial surface area
was 42% higher in the obese group, and so the mitochondrial volume per
unit area was lower (25%) in obesity (Fig. 11C).
We show that mitofusin 2 is crucial to the maintenance and
operation of the mitochondrial network in muscle and nonmuscle cells.
This is based on the following observations: (a) induction of Mfn2 correlates with the generation of the mitochondrial network; (b) repression of Mfn2 in L6E9 myotubes (a 50% reduction)
causes the morphological fragmentation of the mitochondrial network; (c) repression of Mfn2 in myotubes alters the operation of
the mitochondrial network, so instead of acting as an intralumenally connected system, it is divided into independent functional units; and
(d) repression of Mfn2 expression (a 40% reduction)
correlates with a reduction of the mitochondrial network in skeletal
muscle from obese Zucker rats.
Mitochondrial networks in myotubes operate as single functional systems
and damage to one mitochondrial filament collapses the entire
mitochondrial network. This operation is unique to myotubes, and
previous reports on cardiac myocytes or on fibroblasts suggest there
are several independent clusters of electrically connected mitochondria
per cell (3, 4). Alteration of the functional mitochondrial network in
myotubes with lower Mfn2 expression indicates that this protein permits
the operation of the mitochondrial network as an intralumenally
connected system.
Our data also demonstrate that Mfn2 controls mitochondrial metabolism.
This is based on the observations that: (a) repression of
Mfn2 in myotubes (50% reduction) reduces mitochondrial membrane potential by nearly 60% and glucose oxidation by at least 30% and
(b) cellular repression of Mfn2 in 10T1/2 cells (68%
reduction) reduces mitochondrial proton leak and cellular oxygen
consumption (30% reduction) and glucose oxidation (70% reduction),
which occurs in the absence of changes in coupled respiration. Our data
indicate that partial abolition of Mfn2 expression modifies
mitochondrial metabolism in cells. In this connection, we postulate
that Mfn2 helps to maintain the maximal activity of certain components
of the respiratory chain; therefore changes in the expression of Mfn2
may destabilize some of those complexes and/or reduce their activity.
We also show that Mfn2 is reduced by nearly 40% in skeletal muscle
from obese subjects and from obese Zucker rats. This reduction is close
to that obtained in cultured cells by genetic manipulation. In parallel
to a reduction of Mfn2 expression, the mitochondrial network and
mitochondrial size in skeletal muscle from obese Zucker rats were
smaller. In keeping with these observations, smaller mitochondria have
been reported in skeletal muscle from obese subjects (47). The
down-regulation of Mfn2 detected in skeletal muscle from obese subjects
or obese rats together with the observation that Mfn2 promotes
mitochondrial metabolism may explain some of the metabolic alterations
observed during obesity and characterized by impaired muscle glucose
oxidation and fatty acid oxidation (36-39) and reduced cytochrome
c oxidase (48).
Zucker rats are obese because of a loss-of-function mutation in the
leptin receptor (49), and the obesity of this animal model is only
partially explained by its hyperphagia; therefore the underlying
metabolic unbalance is not understood (50). This is crucial to our
understanding of human obesity, a syndrome characterized by leptin
resistance (51). In this regard, the observation that obesity shows
reduced Mfn2 expression and a reduced mitochondrial network, which
results in reduced mitochondrial metabolism in vitro, could
prove to be of central importance. Further studies in rodents after
recombinant ablation of Mfn2 are required to determine whether it
contributes to obesity.
In summary, we have identified Mfn2 as a mitochondrial protein that
plays a role in the control of the morphology and electrochemical operation of the mitochondrial network in cells and in mitochondrial metabolism. Thus, cellular repression of Mfn2 decreases mitochondrial membrane potential and the cellular rate of glucose oxidation and
represses mitochondrial proton leak, which occurs in the absence of
changes in coupled respiration. These observations suggest that Mfn2
plays a role in the pathophysiology of obesity because repression of
Mfn2 gene expression in skeletal muscle from obese subjects may account
for impaired energy expenditure and impaired muscle oxidative capacity
associated with obesity. In all, our data imply a major role of Mfn2 in
mitochondrial energy metabolism and thermogenesis, which when
deregulated may be a key risk factor in the development of obesity.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
= 488 nm) with an output of 11.4 mW was used. The duration of the light
laser irradiation was 60 s, and the diameter of the focused laser
spot was 0.5 µm. The cells were viewed by confocal microscopy before
and 1.5 and 5 min after laser irradiation. The confocal images were
obtained using a Leica TCS 4D laser confocal fluorescence microscope
with a 63× objective at the Serveis Científico-Tècnics,
University of Barcelona.
240 mV. This allows the membrane potential measurement by
determination of red, relative to green, emitted light irrespective of
the number of mitochondria measured per image (28, 29). To measure
differences in mitochondrial membrane potential between control cells
and Mfn-2 knock-out cells, the dual emission of the potentiometric dye
JC-1 was observed, and the red/green fluorescence ratio was measured.
The cells were incubated with 1 µM JC-1 (Molecular Probes) diluted in DMEM with 2% FBS for 20 min at 37 °C. The cells were washed once in DMEM with 2% FBS and viewed in vivo at
the confocal microscope. Z-series stacks (always at the same
nonsaturating conditions) were taken to measure red (597 nm) and green
(539 nm) fluorescence. JC-1 potentiometric method accuracy was
validated using carbonyl cyanide
p-trifluoromethoxyphenylhydrazone (10 µM) and
oligomycin (0.5 µg/ml) to assess minimal and maximal mitochondrial membrane potential either by confocal microscopy or by flow cytometry (data not shown).
80 °C. DNA was isolated
from purified viral particles, and the recombinant viral genome was
verified by restriction enzyme analysis. Viral stocks were titrated by
infecting 293 cells with serial dilutions of the preparation and
counting plaque forming units on the monolayer 15 days after infection.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (53K):
[in a new window]
Fig. 1.
Mfn2 is abundantly expressed in muscle and
induced during myogenesis. A, a poly(A) RNA (2 µg/lane)
membrane containing 12 different human adult tissues was purchased from
Clontech. The blots were probed with
32P-labeled rat Mfn2 cDNA fragment and washed at
stringent conditions. Mfn2 cDNA hybridizes to a transcript of
~4.7 kb. Proper quality and control of loading was substantiated by
hybridization with human -actin cDNA, used as a control probe.
B, total RNA was purified from L6E9 myoblast (Mb)
or myotube (Mt) cells. Mfn2 mRNA was detected after
hybridization with a 1200-bp SacI human Mfn2 fragment as a
cDNA probe. Cytochrome c oxidase subunit-II
(COX-II) mRNA was detected after hybridization with a
500-bp fragment as a cDNA probe. The integrity of RNA in each
sample used and the relative amounts of RNA loaded in each lane were
checked by 28 S ribosomal RNA ethidium bromide staining on the same
gel.
View larger version (45K):
[in a new window]
Fig. 2.
Mfn2 protein is enriched in mitochondria and
undergoes induction in myogenesis. A, extracts enriched in
mitochondria were obtained from brown adipose tissue (BAT),
kidney, skeletal muscle, or heart from rats. Mfn2 was detected in
Western blot assays by using a polyclonal antibody raised against the
peptide LGPKNSRRALMGYNDQVQRP. Western blot assays were performed in the
absence or in the presence of the immunogenic peptide at a
concentration of 400 µg/ml. B, crude homogenates
(H) or fractions enriched in mitochondria (Mito)
were obtained from heart, brown adipose tissue, and kidney in rats.
Mfn2 and Porin were detected in Western blot assays by using specific
antibodies (Ab). C, homogenates (H) or
fractions enriched in mitochondria (Mito) were obtained from
L6E9 myoblasts (Mb) and myotubes (Mt). Mfn2 and
Porin were detected in Western blot assays by using specific
antibodies. Control for protein loading was also checked by Ponceau
staining of protein on Immobilon filters.
View larger version (130K):
[in a new window]
Fig. 3.
The mitochondrial network in muscle cells.
A and B, the mitochondrial network was visualized
by incubation with a monoclonal antibody against Porin and further
incubation with a Texas Red-labeled secondary antibody in L6E9
myoblasts (A; scale bar, 10 µm) or in
L6E9 myotubes (B; scale bar, 10 µm).
C and D, L6E9 myoblasts were irradiated with a
laser beam to perforate mitochondria and to induce discharge of the
membrane potential in the mitochondrial filaments. Pseudocolor images
of the green fluorescence emitted by the monomers of JC-1 were taken
before (C) and after 5 min (D) of the laser
irradiation. Total discharge of mitochondrial membrane potential is
detected as destained of previously stained mitochondria. The
arrows show the places of the laser illumination.
View larger version (72K):
[in a new window]
Fig. 4.
Human Mfn2 overexpression affects the
morphology of mitochondrial filaments in muscle cells. A and
B, L6E9 muscle cells were transiently co-transfected with
human Mfn2 and GFP, and 24 h later, the mitochondrial network was
visualized by incubation with a monoclonal antibody against cytochrome
c oxidase subunit I and further incubation with a Texas
Red-labeled secondary antibody (B; scale bar, 10 µm); transfected cells (GFP-positive) were visualized in
A. C-F, 10T1/2 cells were transiently
transfected with a GFP expression vector (C and
E) or with a GFP and human Mfn2 expression vector
(D and F), and 24 h later, the mitochondrial
network was visualized by MitoTracker staining (C and
D; scale bars, 10 µm) or mitochondria were
visualized at the electron microscope (E and F;
scale bars, 1 µm). The asterisks in
E and F denote mitochondria.
-galactosidase, had no effect on Mfn2 expression (Fig.
5A). Control myotubes or myotubes infected with an
irrelevant adenovirus had an extensive mitochondrial network with large
filaments running longitudinal to the muscle cell (Fig. 5, B
and C). In contrast, AS muscle cells showed discontinuity of
the mitochondrial network (Fig. 5D). Quantitation indicated that 82% of mitochondrial filaments were longer than 5 µm in control cells, whereas only 22% of the total mitochondrial filaments showed that size in AS cells. Illumination of mitochondria in AS myotubes was
associated with a loss of mitochondrial membrane potential that
affected a very reduced extension of the mitochondrial network (Fig.
6, A and B)
compared with control cells (Fig. 6, C and D), supporting the view for a fragmentation of the mitochondrial network into independent functional clusters.
View larger version (95K):
[in a new window]
Fig. 5.
Mfn2 repression alters the morphology of the
mitochondrial network in muscle cells. A, adenoviruses
encoding a mouse DNA sequence (nucleotides 1-366 from AY028170) in
antisense orientation driven by a cytomegalovirus promoter were
generated. L6E9 myotubes were infected with adenoviruses at 100 plaque
forming units/cell either encoding -galactosidase
(
-GAL) or the mouse Mfn2 AS; some L6E9 cells were not
infected (C). Two days after infection, the cells were
scraped, and fractions enriched in mitochondria were obtained. Mfn2 and
Porin were detected in Western blot assays by using specific
antibodies. Control for protein loading was also checked by Ponceau
staining of protein on Immobilon filters. B-D, myotubes
infected with the AS adenoviral vector (D), with
adenoviruses encoding
-galactosidase (C), or not infected
(B) were processed for mitochondria staining with JC-1.
Green monomer fluorescence images are shown. The results are
representative of four independent experiments. Scale bars,
10 µm.
View larger version (58K):
[in a new window]
Fig. 6.
Mfn2 repression alters the operation of the
mitochondrial network in muscle cells. Myotubes infected with the
AS adenoviral vector (C and D) or with
adenoviruses encoding -galactosidase (A and B)
were irradiated with a laser beam to perforate mitochondria and to
induce discharge of the membrane potential in the mitochondrial
network. Pseudocolor images of the green fluorescence emitted by the
monomers of JC-1 were taken before (A and C) and
after 5 min (B and D) of laser irradiation. Total
discharge of mitochondrial membrane potential is detected as destained
of previously stained mitochondria. The arrows show the
place of the laser illumination. The arrowheads show
mitochondrial clusters unaffected after laser illumination in AS cells.
The dotted lines delineate the myotubes. Scale
bars, 10 µm.
-galactosidase did not alter glucose oxidation (Fig. 7A).
One point of note is that not all L6E9 myoblasts are usually
differentiated into myotubes in culture, and near 30% of myoblasts
remain undifferentiated (35); provided that undifferentiated myoblasts
are not infected with adenoviruses, the reduction we observe in glucose
oxidation after AS adenoviral infection represents a substantial
underestimate of the actual inhibition. In these conditions, Mfn2
repression reduced mitochondrial membrane potential (Fig.
7B).
View larger version (16K):
[in a new window]
Fig. 7.
Mfn2 repression impairs glucose oxidation and
mitochondrial membrane potential in L6E9 myotubes. A,
glucose oxidation was determined in L6E9 myotubes previously infected
with adenoviruses at 100 plaque forming units/cell either encoding
-galactosidase (
-GAL) or a mouse Mfn2 AS; glucose
oxidation was also measured in myotubes that were not infected
(C). During the experiment, the cells were in Hanks'
balanced salt medium (2% FBS, 5 mmol/liter glucose) containing 0.32 µCi of [14C](U)-D-glucose, and
14CO2 was trapped and measured. The results are
the means ± S.E. of four independent observations. *,
statistically significant difference between
-GAL and AS cells at
p < 0.05. B, myotubes infected with the AS
adenoviral vector (AS), infected with adenoviruses encoding
-galactosidase (
-GAL), or not infected (C)
were stained with JC-1 potentiometric dye, and the mitochondrial
membrane potential was measured as the ratio between the red
fluorescence (from aggregate formation by the concentrated dye in high
mitochondrial polarized regions) versus green fluorescence
(from JC-1 monomers). The results are the means ± S.E. of eight
independent cells. **, statistically significant difference between
-GAL and AS cells at p < 0.001.
View larger version (29K):
[in a new window]
Fig. 8.
Mfn2 repression impairs glucose oxidation and
mitochondrial metabolism in 10T1/2 cells. A, total RNA was
obtained from wild type (wt) 10T1/2 cells or from cells
stably transfected with the empty vector (mock) or with a mouse Mfn2
antisense sequence (DNA fragment between nucleotides 1 and 366 of mouse
Mfn2 cDNA, AY028170, in antisense orientation and driven by a
cytomegalovirus promoter) (clones AS1 and AS2). Mfn2 mRNA levels
were detected by Northern blot analysis. B, crude protein
extracts were obtained from wild type 10T1/2 cells transfected with the
empty vector (mock) or with different mouse Mfn2 antisense clones (AS1
and AS2). Mfn2 protein abundance was detected by Western blot using a
specific antibody. C, glucose oxidation was determined in
wild type 10T1/2 cells, mock, and AS cells. During the experiment, the
cells attached to 25-cm flasks at logarithmic growth were cultured in
Hanks' balanced salt medium (2% FBS, 5 mmol/liter glucose) containing
0.32 µCi of [14C](U)-D-glucose (Amersham
Biosciences), and 14CO2 was trapped and
measured. The results are the means ± S.E. of four independent
observations. The differences between control and AS cells were
statistically significant at p < 0.05. D,
oxygen consumption from 2 × 106 mock (open
bars) or AS (black bars) cells was determined in a
Clark electrode at different conditions to calculate total oxygen
consumption, mitochondrial or nonmitochondrial oxygen consumption,
coupled oxygen consumption (driving ATP synthesis)
(coupl.resp.) or uncoupled respiration (H+ leak).
The cell respiration rates were expressed as functions of cell number.
The cells were incubated in suspension and at constant agitation in
Hanks' balanced salt medium (2% FBS, 5 mmol/liter glucose).
Respiration insensitive to myxothiazol (200 µM) was
defined as nonmitochondrial, and respiration sensitive to myxothiazol
was defined as mitochondrial. Similarly, respiration sensitive to
oligomycin (80 µg/ml) was defined as coupled respiration, and
respiration insensitive to oligomycin but sensitive to myxothiazol
was defined as respiration driving proton leak or uncoupled
respiration. The results are the means ± S.E. of four independent
experiments. *, statistically significant difference between control
and AS cells at p < 0.05.
-hydroxyacetyl-CoA dehydrogenase (44-46).
View larger version (17K):
[in a new window]
Fig. 9.
Obesity represses Mfn2 gene expression in
skeletal muscle. A, total RNA was purified from skeletal
muscle from lean and obese Zucker rats. Mfn2 mRNA was detected
after hybridization with a 321-base pair fragment (nucleotides
2098-2418 of rat Mfn2 cDNA, U41803) as a cDNA probe. Northern
blot of stem cell factor was performed as a control of the relative
amounts of RNA loaded in each lane. The integrity of RNA in each sample
used were checked by 18 S ribosomal RNA ethidium bromide staining on
the same gel. The data are means ± S.E. of six separate
observations. **, statistically significant difference between lean and
obese rats at p < 0.01. B, total RNA was
purified from skeletal muscle from control or obese subjects. Mfn2
mRNA was detected by competitive-quantitative PCR analysis, and the
data were expressed as attomols of Mfn2 mRNA/µg of total
RNA. Mfn2 mRNA and an internal competitor at different known
concentrations were co-amplified with the same pair of primers:
5'-atgcatccccacttaagcac-3' and 5'-ccagagggcagaactttgtc-3'. Mfn2
concentration is extrapolated from the point at which both products are
amplified to the same extent. B shows the mean ± S.E.
of thirteen and nine independent observations in control and obese
subjects. **, statistically significant difference compared with the
control group at p < 0.005.
View larger version (13K):
[in a new window]
Fig. 10.
Mfn2 protein is repressed in skeletal muscle
from obese Zucker rats and obese subjects. A and
B, fractions enriched in mitochondria were obtained from
skeletal muscle from lean and obese Zucker rats (A) or from
control and obese human subjects (B). Mfn2 and Porin were
detected in Western blot assays by using specific antibodies. Control
for protein loading was also checked by Ponceau staining of protein on
Immobilon filters. The values are expressed relative to control levels
(mean of control group set to 100). *, statistically significant
difference between lean and obese rats at p < 0.05 (A). The difference between control and obese subjects
(B) was statistically significant at p < 0.005.
View larger version (46K):
[in a new window]
Fig. 11.
Skeletal muscle from obese Zucker rats shows
an altered mitochondrial network. Soleus muscles from control rats
(A) or obese Zucker rats (B) were processed to
perform stereological analysis of mitochondria. The muscles were fixed
and sectioned randomly in different orientations and prepared for
electron microscopy. Eighty photographs at 5000 enlargements were
taken, and the mitochondrial surface per unit of mitochondrial volume
was determined by using the vertical sections method. The extent of the
mitochondrial network was estimated as a ratio of the mitochondrial
volume/surface (C). The results are the means ± S.E.
of four independent experiments. Scale bars, 1 µm. **,
statistically significant difference between control obese groups at
p < 0.01.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]() |
ACKNOWLEDGEMENT |
---|
We thank Robin Rycroft for editorial support.
![]() |
FOOTNOTES |
---|
* This work was supported by Dirección General de Investigación Científica y Técnica Grants PM98/0197 and SAF2002-02125, Fundació la Marató de TV3 Grant 991110, Fondo de Investigaciones Sanitarias Grant 00/0125, Grant 1999SGR 00039 from Generalitat de Catalunya, and COST B17 Action.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Recipient of a predoctoral fellowship from the Ministerio de Ciencia y Tecnología, Spain.
¶¶ To whom correspondence should be addressed. Tel.: 34-93-4021519; Fax: 34-93-4021559; E-mail: azorzano@bio.ub.es.
Published, JBC Papers in Press, February 21, 2003, DOI 10.1074/jbc.M212754200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: PBS, phosphate-buffered saline; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; GFP, green fluorescent protein; AS, antisense sequence.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Bakeeva, L. E., Chentsov, Yu. S., and Skulachev, V. P. (1978) Biochim. Biophys. Acta 501, 349-369[Medline] [Order article via Infotrieve] |
2. | Kirkwood, S. P., Munn, E. A., and Brooks, G. A. (1986) Am. J. Physiol. 251, C395-C402[Medline] [Order article via Infotrieve] |
3. | Amchenkova, A. A., Bakeeva, L. E., Chentsov, Y. S., Skulachev, V. P., and Zorov, D. B. (1988) J. Cell Biol. 107, 481-495[Abstract] |
4. | Skulachev, V. P. (2001) Trends Biochem. Sci. 26, 23-29[CrossRef][Medline] [Order article via Infotrieve] |
5. | Nunnari, J., Marshall, W. F., Straight, A., Murray, A., Sedat, J. W., and Walter, P. (1997) Mol. Biol. Cell 8, 1233-1242[Abstract] |
6. | Suelmann, R., and Fischer, R. (2000) Cell Motil. Cytoskelet. 45, 42-50[CrossRef][Medline] [Order article via Infotrieve] |
7. |
Collins, T. J.,
Berridge, M. J.,
Lipp, P.,
and Bootman, M. D.
(2002)
EMBO J.
21,
1616-1627 |
8. | Jensen, R. E., Aiken Hobbs, A. E., Cerveny, K. L., and Sesaki, H. (2000) Micros. Res. Tec. 51, 573-583[CrossRef] |
9. | Shaw, J. M., and Nunnari, J. (2002) Trends Cell Biol. 12, 178-184[CrossRef][Medline] [Order article via Infotrieve] |
10. | Hales, K. G., and Fuller, M. T. (1997) Cell 90, 121-129[Medline] [Order article via Infotrieve] |
11. |
Rapaport, D.,
Brunner, M.,
Neupert, W.,
and Westermann, B.
(1998)
J. Biol. Chem.
273,
20150-20155 |
12. |
Otsuga, D.,
Keegan, B. R.,
Brisch, E.,
Thatcher, J. W.,
Hermann, G. J.,
Bleazard, W.,
and Shaw, J. M.
(1998)
J. Cell Biol.
143,
333-349 |
13. | Guan, K., Farh, L., Marshall, T. K., and Deschenes, R. J. (1993) Curr. Genet. 24, 141-148[Medline] [Order article via Infotrieve] |
14. |
Shepard, K,
and Yaffe, M.
(1999)
J. Cell Biol.
144,
711-719 |
15. |
Wong, E. D.,
Wagner, J. A.,
Gorsich, S. W.,
McCaffery, J. M.,
Shaw, J. M.,
and Nunnari, J.
(2000)
J. Cell Biol.
151,
341-352 |
16. |
Mozdy, A. D.,
McCaffery, J. M.,
and Shaw, J. M.
(2000)
J. Cell Biol.
151,
367-379 |
17. |
Tieu, Q.,
and Nunnart, J.
(2000)
J. Cell Biol.
151,
353-365 |
18. |
Fekkes, P.,
Shepard, K. A.,
and Yaffe, M. P.
(2000)
J. Cell Biol.
151,
333-340 |
19. |
Smirnova, E.,
Shurland, D. L.,
Ryazantsev, S. N.,
and van der Bliek, A. M.
(1998)
J. Cell Biol.
143,
351-358 |
20. | Delettre, C., Lenaers, G., Griffoin, J. M., Gigarel, N., Lorenzo, C., Belenguer, P., Pelloquin, L., Grosgeorge, J., Turc-Carel, C., Perret, E., Astarie- Dequeker, C., Lasquellec, L., Arnaud, B., Ducommun, B., Kaplan, J., and Hamel, C. P. (2000) Nat. Genet. 26, 207-210[CrossRef][Medline] [Order article via Infotrieve] |
21. | Alexander, C., Votruba, M., Pesch, U. E., Thiselton, D. L., Mayer, S., Moore, A., Rodriguez, M., Kellner, U., Leo-Kottler, B., Auburger, G., Bhattacharya, S. S., and Wissinger, B. (2000) Nat. Genet. 26, 211-215[CrossRef][Medline] [Order article via Infotrieve] |
22. |
Santel, A.,
and Fuller, M. T.
(2001)
J. Cell Sci.
114,
867-874 |
23. | Bereiter-Hahn, J. (1990) Int. Rev. Cytol. 122, 1-63[Medline] [Order article via Infotrieve] |
24. | Mora, S., Monden, I., Zorzano, A., and Keller, K. (1997) Biochem. J. 324, 455-459[Medline] [Order article via Infotrieve] |
25. |
Castello, A.,
Rodriguez-Manzaneque, J. C.,
Camps, M.,
Perez-Castillo, A.,
Testar, X.,
Palacin, M.,
Santos, A.,
and Zorzano, A.
(1994)
J. Biol. Chem.
269,
5905-5912 |
26. | Auboeuf, D., and Vidal, H. (1997) Anal. Biochem. 245, 141-148[CrossRef][Medline] [Order article via Infotrieve] |
27. | Andreelli, F., Laville, M., Ducluzeau, P. H., Vega, N., Vallier, P., Khalfallah, Y., Riou, J. P., and Vidal, H. (1999) Diabetologia 42, 358-364[CrossRef][Medline] [Order article via Infotrieve] |
28. | Di Lisa, F., Blank, P. S., Colonna, R., Gambassi, G., Silverman, H. S., Stern, M. D., and Hansford, R. G. (1995) J. Physiol. (Lond.) 486, 1-13[Abstract] |
29. |
Damdimopoulos, A. E.,
Miranda-Vizuete, A.,
Pelto-Huikko, M.,
Gustafsson, J. A.,
and Spyrou, G.
(2002)
J. Biol. Chem.
277,
33249-33257 |
30. | Baddeley, A. J., Gundersen, H. J. G., and Cruz-Orive, L. M. (1986) J. Microsc. (Oxf.) 142, 259-276 |
31. |
Santalucia, T.,
Boheler, K. R.,
Brand, N. J.,
Sahye, U.,
Fandos, C.,
Vinals, F.,
Ferre, J.,
Testar, X.,
Palacin, M.,
and Zorzano, A.
(1999)
J. Biol. Chem.
274,
17626-17634 |
32. | Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8802[Abstract] |
33. | Auestad, N., Korsak, R. A., Morrow, J. W., and Edmond, J. (1991) J. Neurochem. 56, 1376-1386[Medline] [Order article via Infotrieve] |
34. |
Rojo, M.,
Legros, F.,
Chateau, D.,
and Lombes, A.
(2002)
J. Cell Sci.
115,
1663-1674 |
35. |
Canicio, J.,
Gallardo, E.,
Illa, I.,
Testar, X.,
Palacin, M.,
Zorzano, A.,
and Kaliman, P.
(1998)
Endocrinology
139,
5042-5049 |
36. | Astrup, A., Andersen, T., Henriksen, O., Christensen, N. J., Bulow, J., Madsen, J., and Quaade, F. (1987) Int. J. Obesity 11, 51-66[Medline] [Order article via Infotrieve] |
37. | Kelley, D. E., and Mandarino, L. J. (2000) Diabetes 49, 677-683[Abstract] |
38. | Cuendet, G. S., Loten, E. G., Jeanrenaud, B., and Renold, A. E. (1976) J. Clin. Invest. 58, 1078-1088[Medline] [Order article via Infotrieve] |
39. | Kemmer, F. W., Berger, M., Herberg, L., Gries, F. A., Wirdeier, A., and Becker, K. (1979) Biochem. J. 178, 733-741[Medline] [Order article via Infotrieve] |
40. | Crettaz, M., Prentki, M., Zaninetti, D., and Jeanrenaud, B. (1980) Biochem. J. 186, 525-534[Medline] [Order article via Infotrieve] |
41. | Kaplan, M. L., and Oh, S. S. (1991) Int. J. Obesity 15, 809-812[Medline] [Order article via Infotrieve] |
42. |
Turcotte, L. P.,
Swenberger, J. R.,
Zavitz Tucker, M.,
and Yee, A. J.
(2001)
Diabetes
50,
1389-1396 |
43. | Zorzano, A., Tomàs, E., Camps, M., Gumà, A., and Palacín, M. (2002) in Muscle Metabolism (Zierath, J. R. , and Wallberg-Henriksson, H., eds) , pp. 297-312, Taylor and Francis, London |
44. | Wardlaw, G. M., Kaplan, M. L., and Lanza-Jacoby, S. (1986) J. Nutr. 116, 1841-1852[Medline] [Order article via Infotrieve] |
45. |
Torgan, C. E.,
Brozinick, J. T., Jr.,
Kastello, G. M.,
and Ivy, J. L.
(1989)
J. Appl. Physiol.
67,
1807-1813 |
46. | Amessou, M., Fouque, F., Soussi, N., Desbuquois, B., Hainaut, I., Girard, J., and Benelli, C. (1998) Mol. Cell. Endocrinol. 144, 139-147[CrossRef][Medline] [Order article via Infotrieve] |
47. |
Kelley, D. E.,
He, J.,
Menshikova, E. V.,
and Ritov, V. B.
(2002)
Diabetes
51,
2944-2950 |
48. |
Simoneau, J. A.,
Kelley, D. E.,
Neverova, M.,
and Warden, C. H.
(1998)
FASEB J.
12,
1739-1745 |
49. | Phillips, M. S., Liu, Q., Hammond, H. A., Dugan, V., Hey, P. J., Caskey, C. J., and Hess, J. F. (1996) Nat. Genet. 13, 18-19[Medline] [Order article via Infotrieve] |
50. | Buchberger, P., and Schmidt, I. (1996) Am. J. Physiol. 271, R472-R476[Medline] [Order article via Infotrieve] |
51. | Maffei, M., Halaas, J., Ravussin, E., Pratley, R. E., Lee, G. H., Zhang, Y., Fei, H., Kim, S., Lallone, R., Ranganathan, S., Kern, P., and Friedman, J. M. (1995) Nat. Med. 1, 1155-1161[Medline] [Order article via Infotrieve] |
52. | Nagase, T., Seki, N., Ishikawa, K., Ohira, M., Kawarabayasi, Y., Ohara, O., Tanaka, A., Kotani, H., Miyajima, N., and Nomura, N. (1996) DNA Res. 3, 321-329[Medline] [Order article via Infotrieve] |